Security key
36322Q206
Damora Therapeutics, Inc. - Common Stock (DMRA)
CUSIP: 36322Q206
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 55,997,999
- Total 13F value
- $1,450,597,849
- Share change
- +54,597,398
- SEC-reported price per share
- $25.90
- Number of holders
- 64
- Value change
- +$1,414,712,373
- Number of buys
- 59
- Number of sells
- 3
- Shares outstanding
- 61,638,745
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
64
Top holders
10
DMRA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
Damora Therapeutics, Inc. SEC filings
Damora Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 36322Q206
Recent filing periods:
Ownership snapshot
Top reported holders of DMRA - Damora Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Fairmount Funds Managemen...
Disclosed value leader
Fairmount Funds Managemen...
Comparable rows
15/15
Latest evidence
31 Mar 2026
3/4/5
13D/G
13F
Lead comparable stake: 20%
13D/G row: Fairmount Funds Management LLC
Showing 1-6 of 15 holder rows.
Quick read
Fairmount Funds Management LLC leads the comparable SEC ownership view at 20%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Fairmount Funds Management LLC's linked filing trail.
Comparable ownership
Top 5
Fairmount Funds Management LLC
20%
FMR LLC
15%
Avoro Capital Advisors LLC
6.3%
Venrock Healthcare Capital Partne...
6%
Paragon Therapeutics, Inc.
3.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC |
3/4/5
13D/G
Director, 10%+ Owner
|
20%
from 13D/G
|
$190,117,660
8,752,035 shares
mixed-class rows
|
— | 23 Mar 2026 |
| FMR LLC |
13D/G
13F
Company
|
15%
|
$6,650,364
238,878 shares
|
$0 | 28 Nov 2025 |
| Avoro Capital Advisors LLC |
13D/G
|
6.3%
|
—
3,783,000 shares
|
$0 | 31 Mar 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
6%
|
$78,630,443
3,603,595 shares
|
$0 | 09 Feb 2026 |
| Paragon Therapeutics, Inc. |
13D/G
|
3.4%
|
—
2,045,473 shares
|
$0 | 09 Feb 2026 |
| Paramora Holding LLC |
13D/G
|
3.4%
|
—
2,045,473 shares
|
$0 | 09 Feb 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
64
Shares
55,997,999
Rows available
64
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
18
Q1 2026 holders
64
Holder diff
46
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend